At a glance
ClinicalIndex Comparison RecordN/ACompleted· 722 enrolled
Drug / intervention
Blood transfusion at hematocrit value less than 24% +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery
In Brief
A clinical study evaluating Blood transfusion at hematocrit value less than 24% and Blood transfusion at hematocrit value less than 28% for Anemia. Completed, enrolled 722 participants across 2 sites in 2 countries.
Detailed Summary
The primary purpose of this study is to determine the best blood level to begin transfusing red blood cells in individuals undergoing cardiac surgery. The secondary aim is to determine the impact of red cell transfusion on health-related quality of life following surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesIndia, United States
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedApr 2008
Primary CompletionAug 2014
Study CompletionJan 2019
TodayJul 2026
First PostedApr 3, 2008
Enrollment StartMar 1, 2007
Primary CompletionAug 1, 2014
Study CompletionJan 3, 2019
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 18.2 years ago
Interventions
Blood transfusion at hematocrit value less than 24%procedure
transfusion
Blood transfusion at hematocrit value less than 28%procedure
transfusion